For the quarter ending 2025-09-30, DWTX had -$3,272,792 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -15,744,616 | -14,732,305 |
| Loss on foreign exchange | -15,241 | -1,712 |
| Amortization of loan costs | 0 | 52,373 |
| Depreciation | -32,215 | 34,278 |
| Reduction in carrying amount of right-of-use asset | 49,553 | - |
| Loss on debt conversion with related party | 0 | -6,134,120 |
| Acquisition of license for research and development | 12,030,667 | - |
| Deferred tax expense | -1,436 | 190,691 |
| Share-based compensation expense | 48,281 | 149,501 |
| Decrease in prepaid expenses and other current assets | 227,655 | -396,528 |
| (decrease) increase in accounts payable | 86,734 | -738,306 |
| Increase in accrued expenses and other liabilities | 502,654 | -197,264 |
| Net cash used in operating activities | -3,272,792 | -8,708,672 |
| Proceeds from registered direct offering of common stock, net of offering costs | 0 | 4,252,245 |
| Proceeds from loan with related party | 0 | 3,000,000 |
| Net cash provided by financing activities | 0 | 7,252,245 |
| Net decrease in cash | -3,272,792 | -1,456,427 |
| Cash and cash equivalents at beginning of period | 14,847,949 | - |
| Effect of exchange rate changes on cash | 7,980 | - |
| Cash and cash equivalents at end of period | 10,126,710 | - |
Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. (DWTX)